Protalix BioTherapeutics (PLX) Non-Current Assets (2010 - 2026)

Protalix BioTherapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 19.45% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $60.4 million, a 10.65% increase from a year earlier, with the FY2025 full-year figure at $15.7 million, up 17.5% from the prior year.
• Non-Current Assets improved to $16.0 million in Q1 2026 per PLX's latest filing, from $15.7 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $16.0 million in Q1 2026 and bottomed at $10.9 million in Q4 2022.
• The 5-year median for Non-Current Assets is $13.7 million (2024), against an average of $13.5 million.
• Across the five-year window, Non-Current Assets retreated 10.92% in 2022 and jumped 36.55% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $10.9 million in 2022, then jumped by 32.96% to $14.5 million in 2023, then declined by 8.02% to $13.3 million in 2024, then gained by 17.5% to $15.7 million in 2025, then grew by 1.96% to $16.0 million in 2026.
• Per Business Quant, the three latest PLX Non-Current Assets figures stand at $16.0 million (Q1 2026), $15.7 million (Q4 2025), and $15.8 million (Q3 2025).